Dollery Stephen J, Zurawski Daniel V, Gaidamakova Elena K, Matrosova Vera Y, Tobin John K, Wiggins Taralyn J, Bushnell Ruth V, MacLeod David A, Alamneh Yonas A, Abu-Taleb Rania, Escatte Mariel G, Meeks Heather N, Daly Michael J, Tobin Gregory J
Biological Mimetics, Inc., 124 Byte Drive, Frederick, MD 21702, USA.
Wound Infections Department, Bacterial Diseases Branch, Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Vaccines (Basel). 2021 Jan 27;9(2):96. doi: 10.3390/vaccines9020096.
is a bacterial pathogen that is often multidrug-resistant (MDR) and causes a range of life-threatening illnesses, including pneumonia, septicemia, and wound infections. Some antibiotic treatments can reduce mortality if dosed early enough before an infection progresses, but there are few other treatment options when it comes to MDR-infection. Although several prophylactic strategies have been assessed, no vaccine candidates have advanced to clinical trials or have been approved. Herein, we rapidly produced protective whole-cell immunogens from planktonic and biofilm-like cultures of , strain AB5075 grown using a variety of methods. After selecting a panel of five cultures based on distinct protein profiles, replicative activity was extinguished by exposure to 10 kGy gamma radiation in the presence of a antioxidant complex composed of manganous (Mn) ions, a decapeptide, and orthophosphate. Mn antioxidants prevent hydroxylation and carbonylation of irradiated proteins, but do not protect nucleic acids, yielding replication-deficient immunogenic vaccine candidates. Mice were immunized and boosted twice with 1.0 × 10 irradiated bacterial cells and then challenged intranasally with AB5075 using two mouse models. Planktonic cultures grown for 16 h in rich media and biofilm cultures grown in static cultures underneath minimal (M9) media stimulated immunity that led to 80-100% protection.
是一种细菌病原体,通常具有多重耐药性(MDR),可导致一系列危及生命的疾病,包括肺炎、败血症和伤口感染。如果在感染进展之前尽早给药,一些抗生素治疗可以降低死亡率,但对于多重耐药感染,几乎没有其他治疗选择。尽管已经评估了几种预防策略,但没有候选疫苗进入临床试验或获得批准。在此,我们使用多种方法从浮游和生物膜样培养物中快速制备了菌株AB5075的保护性全细胞免疫原。在基于不同蛋白质谱选择了一组五种培养物后,在由锰(Mn)离子、十肽和正磷酸盐组成的抗氧化剂复合物存在下,通过暴露于10 kGy伽马辐射来消除复制活性。锰抗氧化剂可防止辐照蛋白质的羟基化和羰基化,但不保护核酸,从而产生复制缺陷的免疫原性候选疫苗。用1.0×10个辐照细菌细胞对小鼠进行免疫和两次加强免疫,然后使用两种小鼠模型经鼻用AB5075进行攻击。在丰富培养基中培养16小时的浮游培养物和在基本(M9)培养基下静态培养的生物膜培养物刺激了免疫力,从而产生了80-100%的保护作用。